3.30 MB - Academy of Medicine of Malaysia

MANAGEMENT OF HIV INFECTION IN CHILDREN
134 Gibb DM, Duong T, Tookey PA, et al. National Study of HIV in Pregnancy and Childhood
Collaborative HIV Paediatric Study. Decline in mortality, AIDS, and hospital admissions in
perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ.
2003;327:1019.
135 Doerholt K, Duong T, Tookey P, et al. Outcomes for human immunodeficiency virus-
1-infected infants in the United kingdom and Republic of Ireland in the era of effective
antiretroviral therapy. Pediatr Infect Dis J, 2006 May;25(5):420-426.
136 Gortmaker SL, Hughes M, Cervia J, et al .Effect of combination therapy including protease
inhibitors on mortality among children and adolescents infected with HIV-1. N. Engl J Med.
2001 Nov 22;345(21):1522-1528.
137 Granados JMS, Amador JTR, Miguel SF, et al. Impact of highly active antiretroviral
therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected
children. Pediatr Infect Dis J. 2003;22:863-867.
138 De Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of
antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV
Infection in Children and the Italian National AIDS Registry. JAMA. 2000 Jul 12;284(2):
190-197.
139 McConnell MS, Byers RH, Frederick T, et al; Pediatric Spectrum of HIV Disease
Consortium. Trends in antiretroviral therapy use and survival rates for a large cohort of
HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune
Defic Syndr. 2005 Apr 1;38(4):488-494.
140 Resino S, Resino R, Maria Bellón J, et al. Spanish Group of Pediatric HIV Infection. Clinical
outcomes improve with highly active antiretroviral therapy in vertically HIV type-
1-infected children. Clin Infect Dis. 2006 Jul 15;43(2):243-252.
141 Bertolli J, Hsu HW, Sukalac T T, et al. Hospitalization trends among children and youths
with perinatal human immunodeficiency virus infection, 1990-2002. Pediatr Infect Dis J.
2006 Jul;25(7):628-633.
142 Gona P, Van Dyke RB, Williams PL, et al Incidence of opportunistic and other infections in
HIV-infected children in the HAART era. JAMA. 2006 Jul 19;296(3):292-300.
143 Verweel G, Van Rossum AM, Hartwig NG, et al. Treatment with highly active antiretroviral
therapy in human immunodeficiency virus type 1-infected children is associated with a
sustained effect on growth. Pediatrics. 2002 Feb;109(2):E25.
144 Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral
therapy in HIV-infected children participating in Thailand’s National Access to Antiretroviral
Program. Clin Infect Dis. 2005 Jul 1;41(1):100-107.
145 Dunn D; HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of
disease progression in HIV-1-infected children receiving no antiretroviral therapy or
zidovudine monotherapy: a meta-analysis. Lancet. 2003 Nov 15;362(9396):1605-1611.
146 Faye A, Bertone C, Teglas JP, et al. Early multitherapy including a protease inhibitor for
human immunodeficiency virus type 1-infected infants.Pediatr Infect Dis J. 2002
Jun;21(6):518-525.
147 Aboulker JP, Babiker A, Chaix ML, et al. Highly active antiretroviral therapy started in
infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug
resistance outcome. AIDS. 2004 Jan 23;18(2):237-245.
62